SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DECODE GENETICS-*DCGN
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (256)10/6/2006 4:36:10 PM
From: keokalani'nui  Read Replies (1) of 313
 
Both intervene in the 5-leukotrine pathway, though x051 attacks a novel target and is a v. different cpd (chemically). Since the premise of x031 (in-licensed as a late stage, shuttered program at Bayer) was to leapfrog the internal develpment path, your doubts are right on.

All things being equal, if fixing the formulation and restarting P3 takes 12 months you are probably right--x031 will die twice. Bayer royalty vs. proprietary x051, one P3 vs 2 P3 for same indication? No hard financial choices there.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News